Asahi Kasei Acquisition Pays Off With FDA Approval for Novel Herpes Drug

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 12 Oct, 14:44 UTC

Asahi Kasei’s Hovilpri is now approved for treating lesions caused by herpes simplex virus infection. This daily pill came from the $919 million acquisition of AiCuris Anti-Infective Cures. The post Asahi Kasei Acquisition Pays Off With FDA Approval for Novel Herpes Drug appeared first on MedCity…

businessscience

Sources

• T2Asahi Kasei Acquisition Pays Off With FDA Approval for Novel Herpes DrugFierce Biotech / Fierce Healthcare / MedCity / GEN12 Oct, 14:44